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Background: Procalcitonin (PCT)-protocols to guide antibiotic treatment in severe infections are known to be
effective. But less is known about the long-term effects of such protocols on antibiotic consumption under real life
conditions. This retrospective study analyses the effects on antibiotic use in patients with severe sepsis and septic
shock after implementation of a PCT-protocol.
Methods: We conducted a retrospective ICU-database search for adult patients between 2005 and 2009 with
sepsis and organ dysfunction who where treated accordingly to a PCT-guided algorithm as follows: Daily
measurements of PCT (BRAHMS PCT LIAW; BRAHMS Aktiengesellschaft, Hennigsdorf, Germany). Antibiotic therapy
was discontinued if 1) clinical signs and symptoms of infection improved and PCT decreased to ≤1 ng/ml, or 2) if
the PCT value was >1 ng/ml, but had dropped to 25-35% of the initial value within three days. The primary
outcome parameters were: antibiotic days on ICU, ICU re-infection rate, 28-day mortality rate, length of stay (LOS)
in ICU, mean antibiotic costs (per patient) and ventilation hours. Data from 141 patients were included in our
study. Primary outcome parameters were analysed using covariance analyses (ANCOVA) to control for effects by
gender, age, SAPS II, APACHE II and effective cost weight.
Results: From baseline data of 2005, duration of antibiotic therapy was reduced by an average of 1.0 day per year
from 14.3 ±1.2 to 9.0 ±1.7 days in 2009 (p=0.02). ICU re-infection rate was decreased by yearly 35.1% (95% CI −53
to −8.5; p=0.014) just as ventilation hours by 42 hours per year (95% CI −72.6 to −11.4; p=0.008). ICU-LOS was
reduced by 2.7 days per year (p<0.001). Trends towards an average yearly reduction of 28-day mortality by −22.4%
(95% CI −44.3 to 8.1; p=0.133) and mean cost for antibiotic therapy/ patient by −14.3 Euro (95% CI −55.7 to 27.1)
did not reach statistical significance.
Conclusions: In a real-life clinical setting, implementation of a PCT-protocol was associated with a reduced
duration of antibiotic therapy in septic ICU patients without compromising clinical or economical outcomes.
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There is a dramatic increase in antibiotic-resistant infec-
tions [1-3], leading to higher mortality, longer hospital
or intensive care unit (ICU) stays, and increased hospital
costs [3,4]. While timely initiation of antibiotic therapy
in patients with severe sepsis and septic shock is crucial
and has been proven [5], length of antibiotic treatment
in clinical practice often is decided by the attending
clinician by means of his experience.
But, shortening the length of antibiotic courses seems to
play an important role in reducing antibiotic resistance [6]
and its effectiveness has been shown in several studies
[7-9]. In this context, there is rising evidence that a
procalcitonin (PCT)- based algorithm is a useful tool to
support clinical decision when tailoring antibiotic therapy.
Several randomised controlled trials in a variety of settings
showed a reduction in antibiotic duration or an increase
in antibiotic-free days. Clinical outcome either remained
unaffected [10-15] or even was improved, as two studies
revealed a reduction of length of stay (LOS) in the ICU
[16,17]. Furthermore, recent meta-analyses concluded that
PCT-guided antibiotic treatment appears to be safe, re-
duces antibiotic consumption and may also improve out-
come [18-20]. In patients with acute respiratory infections,
a current systematic Cochrane review revealed a signifi-
cant reduction in duration of antibiotic treatment without
negative effects on clinical outcome parameters [21].
Although the effectiveness of PCT-guided antibiotic
therapy has been proven in several randomised clinical
trials, so far less is known about implementation and
effects of such protocols under out-of-study conditions.
For patients with respiratory infections outside the ICU,
two studies demonstrated that following a PCT algo-
rithm significantly reduces antibiotic use without in-
creasing the risk of complications [22,23]. But so far
there is no study that evaluates the long-term effects of
such an algorithm on antibiotic consumption in surgical
ICU patients. Thus, in the present study we analyse the
development of duration of antibiotic treatment in
patients with severe sepsis in a surgical intensive care
unit (ICU) over a five years period after implementation
of a PCT-guided algorithm.
Methods
Patients and data collection
Ethics commission approval was obtained from the
Medical Faculty at Christian Albrecht University of Kiel
(D409/10) for our trial in the surgical intensive care
ward at the West Coast Hospital in Heide. The informed
consent was waived in view of the retrospective and
anonymous nature of the study.
In 2005 we introduced a PCT-guided algorithm as fol-
lows: Daily measurements of PCT (BRAHMS PCT LIAW;
BRAHMS Aktiengesellschaft, Hennigsdorf, Germany) withthe daily routine blood samples. Antibiotic therapy was
discontinued if 1) clinical signs and symptoms of infection
improved and PCT decreased to ≤1 ng/ml, or 2) if the
PCT value was >1 ng/ml, but had dropped to 25-35% of
the initial value within three days (Figure 1).
We conducted a retrospective ICU-database search
for adult patients from our surgical ICU between 2005
and 2009 with a) sepsis and b) organ dysfunction on
presentation as defined by the ACCP/SCCM Consensus
Conference Committee [24] (i.e. gas exchange impair-
ment (partial pressure of arterial oxygen (PaO2)/fraction
of inspired oxygen (FiO2) < 300 mmHg), acute renal
dysfunction (2-fold baseline creatinine increase or urine
output < 0.5 ml/kg for at least two hours), platelet count
below 100,000 cells/mm3, lactate blood concentration
above 2 mmol/l or sepsis induced impaired mental sta-
tus. Patients with sepsis induced mean arterial pressure
below 65 mmHg for ≥ 1 hour despite adequate fluid
resuscitation were classified as having septic shock).
Exclusion criteria were: age under 18 years; known preg-
nancy; bone-marrow transplant or patient undergoing
chemotherapy; infections for which long-term antibiotic
treatment is strongly recommended (e.g. infective endo-
carditis, tuberculosis, anterior mediastinitis after cardiac
surgery) and do-not-resuscitate orders. Also, patients with
an incomplete data set were excluded.
Data were collected for gender, age, Simplified Acute
Physiology Score (SAPS) II, Acute Physiology And
Chronic Health Evaluation (APACHE) Score II, German
Diagnosis Related Groups (G-DRG)-effective cost weight
and for the primary outcome parameters: antibiotic days
on ICU, ICU re-infection rate, LOS in ICU, ventilation
hours, 28-day mortality, and antibiotic costs per patient.
Re-infection was defined as the growth of the initial causa-
tive bacterial strains, taken from the same infection site
after ≥ 48 h of stopping antibiotics, in addition to clinical
signs or symptoms of infection. Mean antibiotic costs per
patient (Euro) were calculated by means of the hospital’s
wholesale prices without costs of administration.
Data analysis
Descriptive statistics are mean ± standard deviation for
patient characteristics or mean ± standard error or 95%
confidence intervals (CI) for outcome. Chi-squared test
was employed for comparison of infection sites over the
years. Number of PCT-measurements per patient for
trend significance over the years was analysed with
Kruskal-Wallis test. Annual means/ percentages of pa-
tient characteristics were first compared for any differ-
ence by analysis of variance (ANOVA) for continuous
characteristics and by logistic regression for categorical
characteristics. P values of the corresponding F tests
and Wald chi-square tests are reported. In a second
step, polynomial contrasts and Cochran-Armitage tests
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Figure 1 PCT-algorithm. PCT-algorithm used in clinical practice during the study period. PCT, procalcitonin. CPR, cardiopulmonary resuscitation. RRT, renal
replacement therapy. * Clinical stabilisation: Haemodynamic stability, improvement of respiratory and renal function,stable metabolic state, improvement of
lactat acidosis, stabilisation of mental state etc.
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observed in patient characteristics over the total study
period. Since in observational studies of moderate size
even non-significant imbalances may bias the results to
a relevant extent, outcome analysis was exclusively
performed by statistical control of the baseline characteris-
tics. Thus, outcome parameters were tested for linear
trends by analysis of covariance (ANCOVA) or logistic re-
gression models with adjustment for the covariates gender,
age, SAPS II, APACHE II and effective G-DRG cost
weight. A p < 0.05 was considered statistically significant.
This method proves to be useful when a retrospective
comparison between different treatment groups is
performed as it compensates for imbalances in important
prognostic variables, which may lead to biases in treatment
effect, and additionally reduces the residual variability in
the statistical models, thus increasing the precision of the
estimates and the power of the applied statistical tests.
The statistical software package SPSS 15.0 (SPSS Inc.,
Chicago, IL, USA) and STATA 11.0 (STATACorp LP,College Station, TX, USA) were used for statistical
analysis.
Results
Data of 4212 ICU-patients from 2005 to 2009 were
screened. Through our data filter, we identified 146
patients with severe sepsis or septic shock. Of these, 5
patients were excluded from the study because of incom-
plete data set. In total, 141 patients were included in the
final analysis set (Figure 2). Comparing the five years of
study period, the number of patients, gender, age, SAPS II,
APACHE II and effective cost weight fluctuated. However,
no significant differences were observed (p > 0.05) with
the exception of a linear trend in APACHE II towards
lower means (p = 0.041) (Table 1). Over the years there
was no significant difference between the infection sites
(Table 2). For number of PCT measurements per patient,
there was significant increasing trend from 2005 to 2009.
The adjusted analysis of 6 outcome parameters from
baseline of 2005 revealed significant average yearly
4212 patients screened for eligibility
4066 patients excluded who did not meet 
inclusion criteria
146 patients with severe sepsis or septic 
shock included
5 patients excluded due to incomplete data 
set
141 patients included in the final data analysis
Figure 2 Screening and inclusion process.
Table 1 Demographic, clinical data and primary outcome parameters
Year 2005 2006 2007 2008 2009 P§ p-value trend#
Patient (n) 38 31 27 27 18
Gender (m/f) 20/18 16/15 14/13 18/9 11/7 0.728 0.289
Age (years)* 68.6 ±15.9 73.8 ±9.5 68.0 ±13.5 67.5 ±13.9 65.4 ±11.6 0.196 0.125
SAPS II * 45.0 ±17.7 43.4 ±17.9 42.5 ±19.8 44.3 ±19.0 37.0 ±10.9 0.603 0.177
Apache II * 20.0 ±8.8 20.5 ±8.8 18.2 ±8.7 17.9 ±9.7 15.6 ±7.2 0.327 0.041
Effective cost weight * 14.8 ±13.6 13.3 ±11.4 17.2 ±14.0 14.5 ±13.6 19.2±18.5 0.623 0.256
Average change per year
Mean 95% CI p
ICU stay (days) 26.0 ± 1.9 19.5 ± 2.2 18.5 ± 2.3 16.3 ± 2.3 15.8 ± 2.8 −2.7 −4.1 to −1.3 < 0.001
Ventilation (hours) 571.4 ± 41.5 455.0 ± 47.3 404.1 ± 49.2 362.0 ± 49.9 467.9 ± 60.9 −42.0 −72.6 to −11.4 0.008
Antibiotic use (days) 14.3 ± 1.2 12.0 ± 1.3 13.8 ± 1.4 12.1 ± 1.4 9.0 ± 1.7 −1.0 −1.9 to −0.2 0.02
Antibiotic costs (EUR/patient) 407.6 ± 57.2 420.7 ± 66.7 426.6 ± 67.7 393.2 ± 68.5 373.9 ± 83.7 −14.3 −55.7 to 27.1 0.495
ICU reinfection rate (proportion) 0.31 ± 0.07 0.37 ± 0.08 0.13 ± 0.06 0.12 ± 0.06 0.08 ± 0.06 −35.1% −53.9% to −8.5% 0.014
28-day mortality (proportion) 0.54 ± 0.06 0.51 ± 0.07 0.55 ± 0.08 0.48 ± 0.07 0.34 ± 0.01 −22.4% −44.3% to 8.1% 0.133
Demographic and clinical data:
* Mean ± standard deviation.
§ F test of ANOVA (continuous characteristic) or Wald chi square test (categorical characteristic) of logistic regression model.
# Linear polynomial contrasts (continuous characteristic) or Cochran-Armitage trend tests (categorical characteristic).
SAPS II, Simplified Acute Physiology Score II.
APACHE II, Acute Physiology And Chronic Health Evaluation Score II.
Primary outcome parameters:
Adjusted Means ± standard error and average yearly change of outcome parameters, with 95 confidence limits (CI) and p values of trend tests from ANCOVA or
logistic regression models with covariates gender, age, SAPS II, APACHE II and effective cost weight.
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Table 2 Sites of infection
2005 2006 2007 2008 2009 p-value
Number of patients 38 31 27 27 18
Pneumonia 21,1% (8) 12,9% (4) 29,6% (8) 22,2% (6) 33,3% (6) n. s.
Abdominal 57,9% (22) 58,1% (18) 63,0% (17) 53,6% (15) 38,9% (7) n. s.
Urogenital 2,6% (1) 3,2% (1) 3,7% (1) 3,7% (1) - n. s.
Soft tissue - 6,5% (2) - - 11,1% (2) n. s.
Others/ unknown 18,4% (7) 19,4% (6) 3,7% (1) 18,5% (5) 16,7% (3) n. s.
n. s., not significant.
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year, p = 0.02) from 14.3 ±1.2 to 9.0 ±1.7 days, rate of
re-infection on ICU (35.1% per year, p = 0.014), ICU-
LOS (2.7 days per year, p < 0.001) and ventilation time
(42 hours per year, p = 0.008). Trends towards reduction
of 28-day mortality by 22.4% per year (95% confidence
interval: -44.3% to 8.1%; p = 0.133) and total cost forFigure 3 Primary outcome parameters, graphical presentation. Annua
mortality and length of ICU stay: means with 95% confidence intervals, adjantibiotic therapy (14.3 Euro per patient and year, p =
0.495) per patient did not reach statistical significance
(Table 1, Figure 3). Of the controlled covariates, effective
cost weight had significant impact on all primary outcome
parameters (p < 0.001). Effective cost weight represents
the amount of reimbursement for the respective payment
in the German Diagnosis Related Groups (G-DRG)l number of days of antibiotic use, ICU re-infection rate, 28-day
usted for gender, age, SAPS II, APACHE II and effective cost weight.
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plexity of the hospital patient population. Furthermore,
case mix index (i. e. the total cost weights of all inpatients
per a defined time period divided by the number of admis-
sions) is a surrogate marker for average patients’ clinical
complexity and is correlated with antibiotic use in hospi-
tals [25]. Age had significant impact on 28-day mortality
(p < 0.001) whereas, for gender, SAPS II and APACHE II




The results of the present study show that after imple-
mentation of a PCT-guided algorithm in 2005 length of
antibiotic therapy in surgical patients with severe sepsis
or septic shock was reduced by an average of 1.0 day
per year from 14.3 ± 1.2 (2005) to 9.0 ± 1.7 days (2009).
This reduction was associated with a significant reduc-
tion in ICU re-infection rate, ICU-LOS and ventilation
hours and non-significant reduction of 28-day mortality
and mean costs of antibiotics per patient. Thus, short-
ening antibiotic therapy did not have negative effects on
clinical or economical outcome.
The length of antibiotic therapy was effectively reduced
in several randomised controlled trials using PCT-guided
algorithms. Thus, it was concluded that implementation
of a PCT-based algorithm may reduce antibiotic exposure
in critically ill, septic patients without compromising clin-
ical outcomes [19]. Hence, our findings are in accordance
with results from randomised controlled trials and further
expand previous studies which confirmed the effectiveness
of PCT-guided antibiotic treatment for non-ICU patients
outside study conditions [22,23].
Algorithm adherence
However, little is known about transfer of such proto-
cols into clinical practice and development of antibiotic
use after implementation of a PCT-guided algorithm.
Implementation of new protocols in an ICU is complex,
multi-professional, and transfer to clinical practice and
optimisation of adherence is time-consuming and
develops over a long period. For example, variability
in compliance with sepsis resuscitation bundles has
recently been shown [26]. And in a large one-day cross-
sectional survey in German ICUs a great discrepancy
between perception of guideline-adherence and clinical
practice was found [27]. Two studies outside the ICU
revealed a high adherence to the PCT algorithm and
confirmed results from RCTs with a shortened duration
of antibiotic treatment [22,23]. But in one study, a
decreased compliance to the algorithm with increasing
severity of illness was found [22]. This is consistent with
RCTs in ICU patients where physicians refused to stopantibiotics despite the opposite suggestion of the PCT-
algorithm in 16-53% [10,15,17]. In our analysis, adher-
ence to the PCT-algorithm was not evaluated over the
study period. But increasing average number of PCT-
measurements per patient from 1.6 ±4.5 in 2005 to
18.6 ±16.4 in 2009, possibly indicates more acceptance
of the PCT-protocol. Further studies are required to
evaluate protocol-adherence in critically ill patients
outside study conditions.Re-infection rate
Interestingly, we found a yearly reduction of 35.1% in
ICU re-infection rate. To our knowledge, so far, six
randomised controlled trials assessed the utility of PCT
in tailoring antibiotic therapy in septic ICU individuals
[10,13,15-17,28]. Only Nobre and Bouadma provided
data of the re-infection rate [10,17]. Nobre and col-
leagues included only a small number of patients (n=79)
of a mixed ICU population and it remains unclear how
many surgical patients were included. However, no dif-
ferences in terms of re-infection rate in the PCT-group
compared to the control group were found. Bouadma
and colleagues showed in 621 septic ICU patients that a
PCT-guided algorithm can reduce the days on antibiotic
therapy. Shortening the therapy did not affect the re-
infection rate. However, less than 10% of the population
were surgical ICU patients. Our findings probably may
be associated with effects from an antimicrobial stew-
ardship program with local guidelines for initial empir-
ical antibiotic treatment and routinely clinical rounds
with an infectious diseases (ID) fellow.Mortality and mechanical ventilation
Furthermore, an average yearly mortality reduction of
22.4% and decreased ventilation hours cannot be solely
explained by implementation of a PCT algorithm. In 2004,
sepsis guidelines for management of severe sepsis and
septic shock were published and extensively implemented
in clinical practice [29]. Impact of interventions from these
guidelines or other implemented strategies during the
study period cannot entirely be excluded in an observa-
tional study of such a long period, even if an extensive
adjustment for covariates took place. However, although
these international guidelines recommend a length of 7 to
10 days for antibiotic therapy in patients with severe
sepsis, in two recent German multi-center studies,
duration of antibiotic treatment was quite longer. In the
VISEP study (2003 – 2005) [30], patients in the different
study groups with a median stay of 13.5 to 16.0 days in the
ICU had a median of zero antibiotic-free days. Similarly,
also a median of zero antibiotic-free days was found in the
MAXSEP study (2007 – 2010) [31] where patients had a
median ICU-LOS of 12 days.
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PCT-algorithms for guidance of antibiotic treatment
may enhance adherence to guidelines since clinicians
may be reassured in their decision to discontinue antibi-
otics by an objective parameter. It must be emphasised
that PCT-algorithms are only a single component in
strategies for optimising antibiotic treatment. Antimicro-
bial stewardship programs are important concepts for a
more rational utilisation of antibiotics [32]. Most ele-
ments of antimicrobial stewardship programs focus on
structural and professional improvements: educational
programs, local guidelines for an appropriate initial
choice of antibiotics, resistance statistics and strategies
(e.g. clinical rounds with infectious diseases fellow) for
streamlining and de-escalating antimicrobial therapy. In
this context, integration of biomarker-guided antibiotic
treatment into antibiotic stewardship programs appears
to be essential [33].
Cost effectiveness
Our study revealed no significant antibiotic cost reduction.
But there seems to be a trend to lower costs over the
years. In our hospital, cost amounted to 14 Euros per
PCT-test. But, a final assessment of cost effectiveness of a
PCT-guided antibiotic therapy cannot be made with the
present study design since there are numerous variables
influencing clinical processes of care, many of which are
difficult to quantify. For example, multi-resistant microor-
ganisms significantly increase treatment expenses due to
requirement of isolation procedures and use of costly
reserve antibiotics. Shortening antibiotic treatment may
have potential to reduce the incidence of multi-resistant
microorganisms and therefore consequential costs. Also,
possibly reduced incremental cost of antibiotic related
adverse effects were not considered in our study. Further-
more, in times of shortage of ICU beds, a reduction in
ICU-LOS leads to economical advantages. An average
yearly reduction of 2.7 days in ICU-LOS like in our study
has potential to conserve resources and enhance ICU
capacity and thus may increase the hospital’s refund. A
previous study confirmed that under certain, assumptions
managing antibiotic treatment with PCT-guided algo-
rithms may reduce overall cost of care [34] and a data
modelling analysis calculated possibly savings of € 1,163
for ICU-patients in the G-DRG system by guiding anti-
biotic treatment with a PCT-algorithm [35]. Nonethe-
less, the cost effectiveness of PCT-guided strategies
needs to be fully evaluated in randomised controlled
trials.
Antimicrobial resistance
Although antibiotic use has been reduced by PCT-guided
strategies, a corresponding reduction in isolation of
antibiotic-resistant organisms has not yet beendemonstrated [33]. Data for correlation between the re-
duced use of antibiotics and impact on a decrease in
multi-resistant organisms were not obtained in our ana-
lysis and further studies are required to answer this
question.
PCT algorithms
Numerous PCT-algorithms with different cut-off values
for starting or discontinuing antibiotic therapy have been
evaluated [10-12,14,16,17,28,36-39]. Most of these trials
have shown the effectiveness of standardised algorithms
to guide antibiotic therapy, even if the same algorithm
was used for different causes of infection. In future,
further studies are required to answer the question
whether we need specific PCT-algorithms for numerous
different causes of severe infection in surgical patients or
whether it suffices to use a general PCT-algorithm to
achieve a more judicious use of antibiotics.
Nonetheless, our data and the results of several studies
and meta-analyses provide that PCT-guided algorithms
seem to be a useful and safe tool in clinical practice to
discontinue antibiotic treatment without negative effects
on clinical or economical outcomes.
Limitations
The main shortcoming of our study is that we did not
compare our results with data from a historical control
group. Thus, it remains unclear to which extent reduc-
tions in antibiotic consumption and improvements in
outcomes are exactly related to the PCT protocol. How-
ever, data from 2005, when the PCT-algorithm was
implemented and number of PCT-measurements per
patient was low, were used as baseline, showing how
antibiotic use improved over the years when the
program was transferred into clinical practice.
In our study 3.4% of all patients were reported to have
severe sepsis whereas prevalence for severe sepsis
including septic shock in Germany’s ICUs is about 11%
[40]. A retrospective search for patients with severe sep-
sis in our ICU database depends on quality of primary
documentation and possibly not all eligible patients
could be identified and included. This may explain the
seemingly low number of patients detected with severe
sepsis in our study. In addition, our ICU was also used
for short-term postoperative and intermediate care and
therefore the rate of patients with the highest risk for
infections was probably low. Nevertheless, a higher total
number of patients with severe sepsis probably would
have increased the validity of our study.
Conclusions
This is the first study that analyses the long-term effects
on antibiotic consumption after implementation of a
PCT-guided algorithm to discontinue antibiotic treatment
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real-life clinical setting, implementation of a PCT-protocol
was associated with a reduced duration of antibiotic
therapy in septic ICU patients without compromising
clinical or economical outcomes. Further studies to as-
sess the impact of PCT-protocols on reduction of resist-
ant organisms are required. Also, algorithm-adherence
and cost-effectiveness of a procalcitonin-guided strategy
should be fully evaluated in a real-life setting of an ICU.
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